Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435886 | 1.00 | SNCA (0.57) | SNCAACHEAPPPTGS1MEN1 | |
| SCHEMBL5431937 | 1.00 | SNCA (0.57) | SNCAACHEAPPPTGS1MEN1 | |
| SCHEMBL4635652 | 0.87 | SNCA (0.58) | SNCAACHEAPPPTGS1SLC28A3 | |
| SCHEMBL5427804 | 0.87 | ACHE (0.50) | SNCAACHEMEN1KMT2ASLC28A3 | |
| SCHEMBL5427382 | 0.87 | ACHE (0.50) | SNCAACHEMEN1KMT2ASLC28A3 | |
| SCHEMBL5437894 | 0.87 | ACHE (0.50) | SNCAACHEMEN1KMT2ASLC28A3 | |
| SCHEMBL17873961 | 0.87 | ACHE (0.50) | SNCAACHEMEN1KMT2ASLC28A3 | |
| SCHEMBL5429570 | 0.82 | CYP1A2 (0.58) | SNCAACHEAPPPTGS1 | |
| SCHEMBL4635920 | 0.80 | SLC28A3 (0.58) | SNCAAPPSLC28A3KDM4E | |
| SCHEMBL27932802 | 0.80 | SLC28A3 (0.49) | SNCAACHESLC28A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173461-A1 | Glycoside prodrug of 5- aminosalicylic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1712555-A1 | PRODRUG COMPRISING 5-AMINOSALICYLATE GLYCOSIDE | Nippon Shinyaku Co., Ltd. (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173461-A1 | Glycoside prodrug of 5- aminosalicylic acid | SI, FUT5, GALE | SNCA 3714/4885ACHE 1092/4885APP 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.